Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $24.0 billion.

  • Addex Therapeutics' Change in Receivables rose 26843.29% to $24.0 billion in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.8 billion, marking a year-over-year increase of 9845.17%. This contributed to the annual value of $105834.9 for FY2024, which is 6898.94% down from last year.
  • As of Q2 2025, Addex Therapeutics' Change in Receivables stood at $24.0 billion, which was up 26843.29% from -$22.1 billion recorded in Q1 2025.
  • Addex Therapeutics' Change in Receivables' 5-year high stood at $423.9 billion during Q4 2024, with a 5-year trough of -$428.7 billion in Q3 2024.
  • In the last 4 years, Addex Therapeutics' Change in Receivables had a median value of $35852.7 in 2022 and averaged -$368.0 million.
  • Over the last 5 years, Addex Therapeutics' Change in Receivables had its largest YoY gain of 49263110067.45% in 2023, and its largest YoY loss of 21192830407.82% in 2023.
  • Quarter analysis of 4 years shows Addex Therapeutics' Change in Receivables stood at -$123736.3 in 2022, then plummeted by 211928304.08% to -$262.2 billion in 2023, then soared by 261.67% to $423.9 billion in 2024, then tumbled by 94.34% to $24.0 billion in 2025.
  • Its Change in Receivables was $24.0 billion in Q2 2025, compared to -$22.1 billion in Q1 2025 and $423.9 billion in Q4 2024.